Based on Phase 2 trial data (Jastreboff et al., NEJM , 2023), the most commonly reported adverse effects of retatrutide include: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (most frequent, particularly during dose escalation) Injection site reactions: Redness, bruising, or mild discomfort Decreased appetite: Generally considered a therapeutic effect but can contribute to nutritional deficiency if severe Increased heart rate: Observed with glucagon receptor agonism
Any third-party brands or services referenced on this site are included for informational purposes only
For weight loss, noticeable results may take longer and are most effective when combined with diet and exercise changes
Who Can Benefit from GLP-1 Weight Loss Treatment
Jazinaki MS, Nosrati M, Chambari M, Jamialahmadi T, Sahebkar A